Novartis Receives FDA Approval for Exelon Skin Patch to Treat Alzheimer’s Disease

Swiss drug maker Novartis AG Monday said it received approval from the U.S. Food and Drug Administration for its Exelon skin patch for the treatment of Alzheimer’s disease.

Novartis, based in Basel, said this was the first approval world-wide for the patch, which delivers the medicine for mild to moderate Alzheimer’s disease patients through a skin patch instead of an oral capsule.